GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cogentix Medical Inc (NAS:CGNT) » Definitions » Beneish M-Score

Cogentix Medical (Cogentix Medical) Beneish M-Score : 0.00 (As of Apr. 27, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Cogentix Medical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Cogentix Medical's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Cogentix Medical was 0.00. The lowest was 0.00. And the median was 0.00.


Cogentix Medical Beneish M-Score Historical Data

The historical data trend for Cogentix Medical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogentix Medical Beneish M-Score Chart

Cogentix Medical Annual Data
Trend Mar08 Mar09 Mar10 Mar11 Mar12 Mar13 Mar14 Mar15 Dec16 Dec17
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.62 -2.45 13.03 - -

Cogentix Medical Quarterly Data
Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3.71 -3.57 -3.64 -

Competitive Comparison of Cogentix Medical's Beneish M-Score

For the Medical Devices subindustry, Cogentix Medical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cogentix Medical's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cogentix Medical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cogentix Medical's Beneish M-Score falls into.



Cogentix Medical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cogentix Medical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1254+0.528 * 1.0327+0.404 * 0.8331+0.892 * 1.0861+0.115 * 1.0549
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9448+4.679 * -0.043415-0.327 * 1.0335
=-2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec17) TTM:Last Year (Dec16) TTM:
Total Receivables was $8.28 Mil.
Revenue was 15.537 + 13.765 + 14.064 + 12.95 = $56.32 Mil.
Gross Profit was 10.187 + 9.395 + 9.406 + 8.456 = $37.44 Mil.
Total Current Assets was $43.68 Mil.
Total Assets was $74.74 Mil.
Property, Plant and Equipment(Net PPE) was $2.43 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.17 Mil.
Selling, General, & Admin. Expense(SGA) was $31.20 Mil.
Total Current Liabilities was $9.38 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was 0.068 + -0.16 + 0.42 + -1.21 = $-0.88 Mil.
Non Operating Income was -0.001 + 0.004 + 0.04 + 0.013 = $0.06 Mil.
Cash Flow from Operations was 0.68 + 2.517 + 1.409 + -2.299 = $2.31 Mil.
Total Receivables was $6.77 Mil.
Revenue was 13.232 + 13.408 + 13.005 + 12.207 = $51.85 Mil.
Gross Profit was 9.242 + 9.038 + 8.917 + 8.405 = $35.60 Mil.
Total Current Assets was $37.52 Mil.
Total Assets was $73.38 Mil.
Property, Plant and Equipment(Net PPE) was $2.12 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.14 Mil.
Selling, General, & Admin. Expense(SGA) was $30.40 Mil.
Total Current Liabilities was $8.91 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(8.276 / 56.316) / (6.771 / 51.852)
=0.146956 / 0.130583
=1.1254

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(35.602 / 51.852) / (37.444 / 56.316)
=0.686608 / 0.664891
=1.0327

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (43.684 + 2.427) / 74.744) / (1 - (37.52 + 2.115) / 73.375)
=0.383081 / 0.45983
=0.8331

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=56.316 / 51.852
=1.0861

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.136 / (3.136 + 2.115)) / (3.167 / (3.167 + 2.427))
=0.59722 / 0.566142
=1.0549

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(31.2 / 56.316) / (30.404 / 51.852)
=0.554017 / 0.586361
=0.9448

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 9.379) / 74.744) / ((0 + 8.909) / 73.375)
=0.125482 / 0.121417
=1.0335

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-0.882 - 0.056 - 2.307) / 74.744
=-0.043415

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cogentix Medical has a M-score of -2.54 suggests that the company is unlikely to be a manipulator.


Cogentix Medical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Cogentix Medical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cogentix Medical (Cogentix Medical) Business Description

Traded in Other Exchanges
N/A
Address
5420 Feltl Road, Minnetonka, MN, USA, 55343
Cogentix Medical Inc is a medical device company. The company designs, develops, manufactures and markets a robust line of high-performance fiberoptic and video endoscopy products under the PrimeSight brand that is used across multiple surgical specialties in diagnostic and treatment procedures. Cogentix offers the Urgent PC Neuromodulation System, a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). It also develops Macroplastique an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence primarily resulting from intrinsic sphincter deficiency.
Executives
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
Brett Reynolds officer: SVP, CFO, Treasurer 5000 W 36TH STREET, MINNEAPOLIS MN 55416
Kenneth A Samet director 800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850
Uri Geiger director 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Growth Partners, L.p. 10 percent owner 6 HACHOSHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Accelmed Growth Partners Management Ltd. 10 percent owner 6 HACHOCHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Accelmed Growth Partners (gp), L.p. 10 percent owner 6 HACHOCHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Accelmed Growth Partners (agp) Ltd 10 percent owner 6 HACHOCHLIM STREET, 6TH FLOOR, HERZLIYA PITUACH L3 4672406
Cheryl Pegus director 40 RAMLAND ROAD, ORANGEBURG CA 10962
Kenneth H Paulus director 5420 FELTL ROAD, MINNETONKA MN 55343
Sven Wehrwein director
Kevin H Roche director
David W Anderson director 519 LYNMERE ROAD, BRYN MAWR PA 19010

Cogentix Medical (Cogentix Medical) Headlines

From GuruFocus

Cognyte Announces Changes to its Board of Directors

By Business Wire 07-11-2023